Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
2021 · Journal of Clinical Oncology · 315 citations
https://doi.org/10.1200/jco.20.03639
T
Toralf Reimer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
439
Papers
10.8K
Citations
49
h-index
157
i10-index
Toralf Reimer is an academic researcher from University of Rostock. The author has contributed to research in topics: Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies. The author has an h-index of 49, co-authored 374 publications.
ORCID: 0000-0003-3014-370XPapers by this author
worksHigher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial
2011 · The Breast · 226 citations
https://doi.org/10.1016/j.breast.2011.07.006
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
2024 · New England Journal of Medicine · 221 citations
https://doi.org/10.1056/nejmoa2313487
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
2024 · New England Journal of Medicine · 168 citations
https://doi.org/10.1056/nejmoa2412063
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
2017 · Annals of Oncology · 167 citations
https://doi.org/10.1093/annonc/mdx494
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
2019 · Journal of Clinical Oncology · 145 citations
https://doi.org/10.1200/jco.18.00028
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat